Press Releases
CITY OF INDUSTRY, Calif. May. 1, 2014 – Prolacta Bioscience, the pioneer in human milk-based nutritional products, today announced the introduction of Prolact CR, the world’s first and only human milk caloric fortifier made from pasteurized human milk cream, for preterm infants in the neonatal intensive care unit (NICU).
Prolact CR is composed of approximately 25% fat, provides 2.5 Cal/mL and contains no added minerals. Prolact CR is used with either mother’s own breast milk or human donor milk to standardize milk at 20 Cal/fl oz, which facilitates individualized fortification for premature infants in the NICU. Standardizing human milk helps these babies increase weight and length while in the NICU. Prolact CR is available by prescription only and is intended for use in the NICU for premature infants.
“In 2009, the American Dietetic Association published a paper detailing that a significant percentage of breast milk actually contains less than 20 calories per fluid ounce,” said Scott Elster, CEO of Prolacta. “Adding Prolact CR to mom’s own or donor breast milk, when less than 20 Kcal/Oz, provides the energy that preterm infants need and is an important tool in the management of these babies.”
The results of a randomized clinical study of 78 premature infants to evaluate the effects of adding human milk-derived cream product to a standard feeding regimen in preterm infants will be presented at the upcoming Pediatric Academic Societies and Asian Societies for Pediatric Research conference taking place in Vancouver, Canada on May 3-6, 2014.
Prolact CR joins a complete line of human milk-based, nutritional products that are clinically proven to improve health outcomes of critically ill preemies. Prolacta’s complete line of NICU nutritional products includes Prolact+ H2MF® Human Milk Fortifier, PremieLact and Prolact HM Standardized Donor Milk, and Prolact RTF Human Milk-based Premature Infant Formula. Prolacta’s full line of human milk-based products helps hospitals meet the American Academy of Pediatrics policy statement regarding breastfeeding and the use of human milk. Recommendations include the use of human milk for all preterm infants, whether mother’s own milk or pasteurized donor human milk. Please join in on the conversation about Prolacta.
Prolacta Bioscience, Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. The company pioneered the development of human milk-based nutritional products to meet the needs of critically ill, premature infants in the NICU and leads the industry in the quality and safety of nutritional products made from breast milk. Prolacta operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk. For more information please visit www.prolacta.com.